A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback